webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

EMCC-Peg8-Lys-PNP

  CAS No.:   Cat No.: BADC-01430 4.5  

EMCC-Peg8-Lys-PNP is a maleimide- and NHS ester-containing ADC linker with peptide sequence, supporting stable cysteine conjugation and protease-sensitive drug release in antibody-drug conjugates.

EMCC-Peg8-Lys-PNP

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C77H98N10O20
Molecular Weight
1483.68

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
EMCC-1; EMCC-PEG8-Lys(Mtt)-PAB-PNP
IUPAC Name
4-((S)-35-(4-(((1r,4r)-4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)methyl)-1H-1,2,3-triazol-1-yl)-2-(4-((diphenyl(p-tolyl)methyl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontanamido)benzyl (4-nitrophenyl) carbonate
InChI
InChI=1S/C77H98N10O20/c1-58-15-23-64(24-16-58)77(62-10-4-2-5-11-62,63-12-6-3-7-13-63)80-33-9-8-14-69(75(93)81-65-25-19-60(20-26-65)55-106-76(94)107-68-29-27-67(28-30-68)87(95)96)82-71(89)57-105-56-70(88)78-34-36-97-38-40-99-42-44-101-46-48-103-50-51-104-49-47-102-45-43-100-41-39-98-37-35-85-54-66(83-84-85)52-79-74(92)61-21-17-59(18-22-61)53-86-72(90)31-32-73(86)91/h2-7,10-13,15-16,19-20,23-32,54,59,61,69,80H,8-9,14,17-18,21-22,33-53,55-57H2,1H3,(H,78,88)(H,79,92)(H,81,93)(H,82,89)/t59-,61-,69-/m0/s1
InChIKey
BPCVATPJLWWNEK-SSLGMICESA-N

EMCC-Peg8-Lys-PNP, a specialized chemical compound with diverse applications in biomedicine and materials science, unveils intricate properties for a myriad of uses. Here are four key applications of EMCC-Peg8-Lys-PNP:

Targeted Drug Delivery: Through the utilization of EMCC-Peg8-Lys-PNP, researchers pioneer advanced targeted drug delivery systems that redefine therapeutic interventions. The PEGylation process enhances the solubility and stability of therapeutic agents, while the lysine residue provides a strategic site for drug conjugation. This intricate process enables the precise delivery of medications to specific tissues or cells, minimizing adverse effects and maximizing therapeutic efficacy with precision.

Bioconjugation: The versatile functional groups of EMCC-Peg8-Lys-PNP play a pivotal role in bioconjugation techniques that propel the frontiers of diagnostic and therapeutic applications forward. This compound intricately links to proteins, antibodies, or other biomolecules to craft tailored conjugates for a myriad of purposes. Such conjugates find utility in imaging, targeting specific biomarkers, or delivering therapeutic payloads directly to disease sites.

Nanomedicine: Within the domain of nanomedicine, EMCC-Peg8-Lys-PNP emerges as a vital component due to its multifunctionality and advanced properties. The PEG moiety bestows stealth characteristics upon nanoparticles, minimizing immune recognition and clearance from the bloodstream. This sophisticated feature prolongs the circulation time of nanoparticles, facilitating the efficient delivery of drugs or imaging agents to targeted sites.

Biosensing: The adoption of EMCC-Peg8-Lys-PNP in the development of cutting-edge biosensors for detecting specific biomolecules underscores its versatility and complexity. The PEGylated structure of this compound assumes a critical role in mitigating non-specific binding, thereby enhancing the specificity and sensitivity of biosensors to unprecedented levels. This groundbreaking application resonates in clinical diagnostics, environmental monitoring, and research settings, enabling the swift detection of pathogens, proteins, or other analytes with a sophistication mirroring the complexity of biological systems.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: FR-901464 | NHS-PEG2-SS-PEG2-NHS | N-(2-(2,6-Dimethylphenoxy)ethyl)-4-Formylbenzamide | Propargyl-O-C1-amido-PEG4-C2-NHS ester | Q Pr | Q Bu-i | DBCO-PEG4-GGFG-DX8951 | N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide | N-(2-(4-Chlorophenoxy)ethyl)-4-Formylbenzamide | 2,5-Dioxopyrrolidin-1-yl 3-((3-((3-(trityloxy)propanoyl)oxy)propanoyl)oxy)propanoate | EMCC-Peg8-Lys-PNP
Send Inquiry
Verification code
Inquiry Basket